Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Cell Immunol ; 277(1-2): 1-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22795896

RESUMO

CD55, CD59, CD35 and CD46 are cell membrane proteins that have regulatory properties on the activation of the complement cascade. Deficiency in the expression of these proteins may be associated with lower protection of healthy cells against complement mediated lysis and also with the accumulation of immune complexes in tissues. Few studies assess the expression of these proteins in patients with SLE and the mechanisms that regulate reduction in cellular expression, whereas its impact on manifestations of systemic lupus erythematosus is still unknown.


Assuntos
Proteínas do Sistema Complemento/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Complexo Antígeno-Anticorpo/imunologia , Antígenos CD/imunologia , Células Sanguíneas/imunologia , Feminino , Humanos , Masculino
2.
Clin Dev Immunol ; 2012: 725684, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22761633

RESUMO

CD55, CD59, CD46, and CD35 are proteins with complement regulatory (Creg) properties that ensure cell and tissue integrity when this system is activated. The aim of this study was to evaluate the Creg expression on peripheral blood cells from SLE patients and its association with cytopenia and disease activity. Flow cytometric analyses were performed on blood cells from 100 SLE patients and 61 healthy controls. Compared with healthy controls, we observed in SLE patients with lymphopenia and neutropenia decreased expression of CD55, CD59, and CD46 (P < 0.05). In SLE patients with anemia, CD59 and CD35 were decreased on red blood cells. Furthermore, there was a negative correlation between CD55 and CD59 on neutrophils and the disease activity. The results suggest there is an altered pattern of Creg expression on the peripheral blood cells of SLE patients, and the expression is correlated with disease activity and/or with activation of the complement system.


Assuntos
Antígenos CD/metabolismo , Células Sanguíneas/metabolismo , Proteínas do Sistema Complemento/metabolismo , Lúpus Eritematoso Sistêmico/metabolismo , Adulto , Células Sanguíneas/imunologia , Antígenos CD55/metabolismo , Antígenos CD59/metabolismo , Proteínas do Sistema Complemento/imunologia , Eritrócitos/metabolismo , Feminino , Humanos , Imunofenotipagem , Lúpus Eritematoso Sistêmico/imunologia , Masculino , Proteína Cofatora de Membrana/metabolismo , Pessoa de Meia-Idade , Monócitos/metabolismo , Neutrófilos/metabolismo , Receptores de Complemento 3b/metabolismo
3.
Rev. bras. reumatol ; 51(5): 503-510, nov. 2011. ilus, tab
Artigo em Português | LILACS | ID: lil-599946

RESUMO

A artrite reumatoide (AR) é uma doença autoimune, associada à sinovite poliarticular inflamatória, que acomete principalmente as articulações periféricas. Cerca de 1 por cento da população mundial é afetada, sendo duas a três vezes mais prevalente em mulheres. Apresenta patogênese complexa e multifatorial. A sinóvia das articulações afetadas é infiltrada por linfócitos T e B, macrófagos e granulócitos. A sinóvia reumatoide adquire características proliferativas, formando o pannus, e invade a cartilagem articular e o osso, levando à destruição da arquitetura normal da articulação e à perda de função. A diminuição da expressão de proteínas reguladoras do complemento (PCR) parece desempenhar papel importante na atividade da AR, associada ao agravamento dos sintomas clínicos. A superativação do sistema complemento (SC) é a causa da exacerbação da doença em vários modelos de doenças autoimunes. O presente artigo tem por objetivo revisar os principais aspectos relacionados à regulação do SC na AR, a fim de propiciar melhor compreensão do potencial papel desse sistema na fisiopatologia e na atividade da doença.


Rheumatoid arthritis (RA) is an autoimmune disease associated with polyarticular inflammatory synovitis affecting mainly peripheral joints. It affects approximately 1 percent of the world population, being two to three times more prevalent in women. Rheumatoid arthritis has a complex and multifactorial pathogenesis. The synovium of the affected joints is infiltrated by T and B lymphocytes, macrophages, and granulocytes. The rheumatoid synovium has proliferative characteristics, forming the pannus, which invades cartilage and bone, leading to normal architecture destruction and function loss. The decreased expression of complement regulatory proteins (CRP) seems to play an important role in RA activity, and is associated with worsening of the clinical symptoms. In several models of autoimmune diseases, the overactivation of the complement system (CS) is the cause of disease exacerbation. This article aimed at reviewing the main aspects related to CS regulation in RA in order to provide a better understanding of the potential role of this system in the pathophysiology and activity of the disease.


Assuntos
Humanos , /biossíntese , /biossíntese , /biossíntese , Artrite Reumatoide/imunologia , /biossíntese
4.
Rev Bras Reumatol ; 51(5): 503-10, 2011.
Artigo em Inglês, Português | MEDLINE | ID: mdl-21953001

RESUMO

Rheumatoid arthritis (RA) is an autoimmune disease associated with polyarticular inflammatory synovitis affecting mainly peripheral joints. It affects approximately 1% of the world population, being two to three times more prevalent in women. Rheumatoid arthritis has a complex and multifactorial pathogenesis. The synovium of the affected joints is infiltrated by T and B lymphocytes, macrophages, and granulocytes. The rheumatoid synovium has proliferative characteristics, forming the pannus, which invades cartilage and bone, leading to normal architecture destruction and function loss. The decreased expression of complement regulatory proteins (CRP) seems to play an important role in RA activity, and is associated with worsening of the clinical symptoms. In several models of autoimmune diseases, the overactivation of the complement system (CS) is the cause of disease exacerbation. This article aimed at reviewing the main aspects related to CS regulation in RA in order to provide a better understanding of the potential role of this system in the pathophysiology and activity of the disease.


Assuntos
Artrite Reumatoide/imunologia , Antígenos CD55/biossíntese , Antígenos CD59/biossíntese , Proteína Cofatora de Membrana/biossíntese , Receptores de Complemento 3b/biossíntese , Humanos
5.
Rev. bras. hematol. hemoter ; 33(3): 202-206, June 2011. ilus, tab
Artigo em Inglês | LILACS | ID: lil-596322

RESUMO

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia. METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated. RESULTS: Eight cases (16.7 percent) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5 percent vs. 27.5 percent; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03). CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Leucemia-Linfoma Linfoblástico de Células Precursoras B , Prognóstico
6.
Rev Bras Hematol Hemoter ; 33(3): 202-6, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-23049296

RESUMO

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia. METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated. RESULTS: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03). CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA